TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Days Required for the Wound to Heal Completely
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants with Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants with Serious Adverse Events (SAEs) and Medically-Attended AEs
Endpoint domain: Adverse events/effects
Primary endpoint: confirmed response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events and Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour blood glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prescription status of Antithrombotic Agents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of re-treatment injections of anti-VEGF (Lucentis) therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects losing less than 15 ETDRS letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Flow-mediated Brachial Artery Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete pathological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Depression, Anxiety and Stress Scale (DASS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CAGE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AlloSure value change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages Of Subjects Achieving Seroconversion Against A/H5N1 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AE), After Any Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Increment in glucagon stimulated C - peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Weight, Vital Signs, and Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anatomical and functional lesions of the middle ear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Dyspnea on daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Renal function monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hepatic function monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS parts II (averaged on and off)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off time during waking hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change on the Burke Fahn Marsden Dystonia Rating Scale (BFMDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of exchangeable zinc pool (EZP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: resolution of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Percentage of Participants With Sustained Virologic Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight reduction of >= 5 percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PANSS positive syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Collection of urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Mitral Regurgitation to optimal or acceptable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pathologically Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apathy Evaluation Scale Clinical Version total score after rTMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients achieving SUVmax reduction of 20% or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differential time to positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoarthritis-specific functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distribution within high-grade gliomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change of optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vitamin D metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peritoneal cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathological response to NPLD, paclitaxel and lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of post-extubation airway obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change from baseline Alzheimer's Disease Assessment- cognitive subscale at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline Rey auditory verbal learning score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline Trail Making B-A score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline brain-derived neurotrophic factor level at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of pruritis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of viable fetuses at 20 weeks gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Plasma CD154 level dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of Insulin Infusion Set Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in power of Body and facial Muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Images quality for cervical and intracranial arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hyperphagic access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Entamoeba Gingivalis in dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pressure required to keep open airway during auto-CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Reporting Reproductive Coercion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Intimate Partner Violence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Sexual Intimate Partner Violence
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Uptake of a Modern Contraceptive Method
Endpoint domain: Life impact
Primary endpoint: Any-severity fall-related hemorrhagic events rate
Endpoint domain: Adverse events/effects
Primary endpoint: BORG-RPE rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of women with malignant adnexal mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of adaptive Right Ventricular (RV) pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with Actonel 35 mg
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Potentially Clinically Significant Hematology Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Blood Chemistry Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Potentially Clinically Significant Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Vital Sign Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological modifications to immune cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Rhinosinusitis Disability Index (RSDI) Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Graft loss not due to death of the patient
Endpoint domain: Mortality/survival
Primary endpoint: Biopsy-proven clinical acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subclinical T-cell mediated rejection in 1-year surveillance biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interstitial fibrosis / tubular atrophy with inflammation (IFTA+i)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body and abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulated headache intensity and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS of low back pain or neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS of radiating pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole body protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Completed HPV Vaccine Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of predictive model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically definitive recurrent bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients with a viral load < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinical success with lumbar puncture procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of clinical success with intravenous procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endurance measure (STEEP treadmill test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: blood lipid lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Curve (AUC) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of dietary polyphenols and methylxanthines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area under the concentration-time curve of the analyte in plasma from zero time to 12 hours (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentration in plasma at 6 hours after drug administration (Cp6h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall outcomes in CADASIL patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of nocturia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intracranial Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Symbol Digit Modalities Test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Wisconsin Card Sorting Test (WCST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Digit Spans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Disease Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Microbiome heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Local Breast Tumor Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients who have a significant toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on 0-100 mm VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) of skin blood perfusion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Proportion of eligible patients enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Visual Analogic Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Objective Sleep Duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sleep Efficiency as Assessed by Actigraphy
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Area under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculatory function as assessed by perfused vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival in ESR1-mut Subjects
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival in All Subjects
Endpoint domain: Mortality/survival
Primary endpoint: Peak Inspiratory Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inhaled Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients' Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants with Antibody Levels ≥ 0.10 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol
Endpoint domain: Adverse events/effects
Primary endpoint: Effect Size for Change in Behavioral Index of Inhibitory Control - RT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reparative ability of varnish on caries affected dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progress free survival (PFS) rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive nasal swab and serological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain classification change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm strength change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the amplitude of arm movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Upper limb disability change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Caregiver-Child Interaction (CCX)-joint engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Short Play and Communication Evaluation (SPACE)- joint engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Prevalence of cephalosporin resistance in intraoperative biliary cultures
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of Group B streptococcus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of malignant or benign lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Solicited Systemic AE Signs and Symptoms 7 Days Following the Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Serious AE 24 Weeks Following the Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Resource utilization for diagnostic tests and encounters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Baseline phosphorylated RB levels in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in weekly frequency of cluster headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Refusal Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Follow up Completion Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ED-LINC Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Health Questionnaire (PHQ9) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to First GH Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change From Baseline in Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: steatosis progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum administered dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Genital tract inflammation or epithelial disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-Hypopnea-Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mobility Prevalence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median Number of Trips Per Person
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CareConekta Feasibility: Same Phone at Follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Hospital Costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Complete Response Rate (CR or CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent reduction in excess arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes